



June 27 , 2012

TMRC Co., Ltd.

Approval of formulation patent for TM-411 capsule by US Patent & Trademark Office

TMRC announces that formulation patent for TM-411(tamibarotene) capsule has been approved by US Patent & Trademark Office.

The patent is characterized by a method of manufacture of pharmaceutical compositions comprising propylene glycol ester solutions of TM-411 stably encapsulated in a soft capsule.

In addition to the existing process patent for polymorphism of TM-411, the formulation patent expands the duration of the patent life and would contribute to the mid or long term growth of TM-411 revenue.

The formulation patent for soft capsule was also approved on March 28 in New Zealand.

< Summary >

Countries applied	:	US, EU, Japan, China, Australia etc.
International Application No.	:	PCT/JP2008/056073
Registry No.	:	US; not yet determined New Zealand; 580209
Invention	:	Tamibarotene Capsule
Patent Holder	:	TMRC Co., Ltd.

• **TMRC Co., Ltd.**

Head office : 1-10-11, Hamamatsucho, Minato-ku, Tokyo 105-0013, JAPAN
Paid-in capital: Yen 50 Mil.
Representative: Hisao Ekimoto, Ph.D. (President &CEO)
Business activity: Development, Licensing and Marketing of innovative anti-cancer Drugs
URL : <http://www.tmrc.co.jp/english/index.html>